<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516750</url>
  </required_header>
  <id_info>
    <org_study_id>TRIC-UHA-GU-03-01</org_study_id>
    <secondary_id>CDR0000561303</secondary_id>
    <nct_id>NCT00516750</nct_id>
  </id_info>
  <brief_title>Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin</brief_title>
  <official_title>Phase II Clinical Trial Concerning Gene Expression Profiling to Predict the Chemosensitivity of Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, and&#xD;
      cisplatin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)&#xD;
      may kill more tumor cells. Evaluating blood or tissue samples from patients with cancer may&#xD;
      help doctors learn more about changes that occur in DNA, identify biomarkers related to&#xD;
      cancer, and predict how well patients will respond to combination chemotherapy.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying gene expression profiling to see how well it works&#xD;
      in predicting response to treatment in patients with invasive bladder cancer receiving&#xD;
      methotrexate, vinblastine, doxorubicin, and cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Analyze the correlation between gene expression profile and the effect of chemotherapy&#xD;
           and detect the significant cluster of genes useful to predict chemosensitivity.&#xD;
&#xD;
        -  Confirm the reduction in original tumor size in patients with invasive bladder cancer&#xD;
           treated with methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Determine the overall survival rate in patients treated with this regimen.&#xD;
&#xD;
        -  Assess the reduction in size of metastatic lesions in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive methotrexate on days 1, 15, and 22, vinblastine on days 2, 15, and 22,&#xD;
      doxorubicin hydrochloride and cisplatin on day 2. Treatment repeats every 4 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patient samples will be collected for gene expression profiling.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to lack of enrollment.&#xD;
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of genes associated with sensitivity to the chemotherapy in tumor size reduction of original bladder tumor</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size reduction of metastatic lesion</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of invasive bladder cancer&#xD;
&#xD;
          -  Must be confirmed by chest and abdominal CT scan OR pelvic MRI scan and transurethral&#xD;
             biopsy (with definitive muscle invasion &gt; T2) within 4 weeks prior to registration&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x upper limit of normal&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No liver cirrhosis&#xD;
&#xD;
          -  No ischemic cardiovascular disease or arrhythmia for which treatment is necessary&#xD;
&#xD;
          -  No cardiac infarction within the past 6 months&#xD;
&#xD;
          -  No interstitial pneumonia, pulmonary fibrosis, or any other diseases by which oxygen&#xD;
             inhalation therapy is needed&#xD;
&#xD;
          -  No active cancerous lesion other than upper urinary tract tumor&#xD;
&#xD;
          -  No high fever or any other infectious symptom&#xD;
&#xD;
          -  No uncontrolled hypertension or diabetes mellitus&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Ogawa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kyoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga Medical Center for Adults</name>
      <address>
        <city>Moriyama</city>
        <state>Shiga</state>
        <zip>524-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Kyoto Medical Center</name>
      <address>
        <city>Kyoto</city>
        <zip>612-0861</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Red Cross Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>543-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

